Commentary led by Marleen Kok highlights all questions in early TNBC post-KN522
Erika Hamilton shared on X:
“This commentary led by Marleen Kok highlights all the pertinent questions in early TNBC post-KN522: Do we need this much chemo for everyone? What is the adjuvant component benefit from immunotherapy? What about biomarkers to tell us who really benefits?”
Authors: Marleen Kok, Robbert-Jan Gielen, Sylvia Adams, Jochen K. Lennerz, Priyanka Sharma, Sibylle Loibl, Erin Reardon, Gabe Sonke, Sabine Linn, Suzette Delaloge, Denis Lacombe, Tim Robinson, Sunil Badve, Miguel Martin, Justin M. Balko, Michail Ignatiadis, Giuseppe Curigliano, Antonio C. Wolff, Elizabeth A. Mittendorf, Sherene Loi, Lajos Pusztai, Sara M. Tolaney, Roberto Salgado
Source: Erika Hamilton/X
Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.
Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.
Marleen Kok is a medical oncologist and associate professor in translational cancer research at the Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands, where she leads the breast cancer immunotherapy program and a translational breast cancer immunology laboratory. She is working at the forefront of innovative immunotherapy trials.
The mission of her clinical and translational team is to improve immunomodulatory treatments for breast cancer patients. She is the recipient of The 2023 Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Grant to investigate cancer-immune interactions in-depth in patients with TNBC in the context of anti-PD1 treatment.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023